These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
694 related items for PubMed ID: 11389085
1. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Böhm BO, Schmid RM. Cancer Res; 2001 Jun 01; 61(11):4526-35. PubMed ID: 11389085 [Abstract] [Full Text] [Related]
2. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M. Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446 [Abstract] [Full Text] [Related]
3. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Gallel P, Pallares J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar-Asenjo V, Lagarda H, Mauricio D, Encinas M, Matias-Guiu X. Hum Pathol; 2008 Jul 15; 39(7):994-1001. PubMed ID: 18508109 [Abstract] [Full Text] [Related]
4. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. Madrid LV, Mayo MW, Reuther JY, Baldwin AS. J Biol Chem; 2001 Jun 01; 276(22):18934-40. PubMed ID: 11259436 [Abstract] [Full Text] [Related]
5. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM. J Natl Cancer Inst; 2004 Aug 18; 96(16):1231-9. PubMed ID: 15316058 [Abstract] [Full Text] [Related]
6. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F. J Natl Cancer Inst; 2004 Jul 07; 96(13):1006-14. PubMed ID: 15240784 [Abstract] [Full Text] [Related]
7. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M. Am J Pathol; 2004 Aug 07; 165(2):511-21. PubMed ID: 15277225 [Abstract] [Full Text] [Related]
9. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM. Cancer Res; 2005 Mar 01; 65(5):1729-37. PubMed ID: 15753368 [Abstract] [Full Text] [Related]
10. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M. Proc Natl Acad Sci U S A; 1997 Apr 01; 94(7):3330-5. PubMed ID: 9096393 [Abstract] [Full Text] [Related]
11. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells. Hennige AM, Lammers R, Arlt D, Höppner W, Strack V, Niederfellner G, Seif FJ, Häring HU, Kellerer M. Mol Cell Endocrinol; 2000 Sep 25; 167(1-2):69-76. PubMed ID: 11000521 [Abstract] [Full Text] [Related]
12. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, Kracht M, Schmitz ML. J Immunol; 2004 May 15; 172(10):6336-44. PubMed ID: 15128824 [Abstract] [Full Text] [Related]
13. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Int J Cancer; 2003 Jul 20; 105(6):735-46. PubMed ID: 12767057 [Abstract] [Full Text] [Related]
14. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM. Mol Cancer; 2017 Jan 26; 16(1):24. PubMed ID: 28122586 [Abstract] [Full Text] [Related]
15. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M. Oncogene; 1999 Jul 01; 18(26):3919-22. PubMed ID: 10445857 [Abstract] [Full Text] [Related]
16. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Drosten M, Stiewe T, Pützer BM. Hum Gene Ther; 2003 Jul 01; 14(10):971-82. PubMed ID: 12869215 [Abstract] [Full Text] [Related]
17. Regulation and function of IKK and IKK-related kinases. Häcker H, Karin M. Sci STKE; 2006 Oct 17; 2006(357):re13. PubMed ID: 17047224 [Abstract] [Full Text] [Related]
18. RET activation by germline MEN2A and MEN2B mutations. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L. Oncogene; 1995 Dec 07; 11(11):2419-27. PubMed ID: 8570194 [Abstract] [Full Text] [Related]
19. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Reynolds L, Jones K, Winton DJ, Cranston A, Houghton C, Howard L, Ponder BA, Smith DP. Oncogene; 2001 Jul 05; 20(30):3986-94. PubMed ID: 11494127 [Abstract] [Full Text] [Related]
20. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA, Cox AD. Oncogene; 2000 Sep 28; 19(41):4685-94. PubMed ID: 11032018 [Abstract] [Full Text] [Related] Page: [Next] [New Search]